Study Information
| Title: | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer  |
| Status: | Recruiting participants |
| Conditions: | Esophageal Cancer; Gastric Cancer |
| Interventions: | Drug: bevacizumab; Drug: trastuzumab; Drug: oxaliplatin; Drug: capecitabine |
| Institutions: | Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital |
| Health Topics: | Esophageal Cancer, Head and Neck Cancer, Stomach Cancer |
Contact Information
Dana-Farber Cancer Institute
Boston, MA 02115
Massachusetts General Hospital
Boston, MA 02114